Form 4: Corcept CBO Robb Buys Shares, Receives Equity Awards

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported the acquisition of 499 common shares and 499 unvested restricted stock awards, alongside a tax-related share withholding.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc. (CORT), reported transactions involving the company's common stock.
• On March 2, 2026, Robb purchased 499 shares of common stock at a price of $35.97 per share through a purchase plan.
• Concurrently, Robb was granted 499 unvested restricted stock awards under the same purchase plan, with a deemed acquisition price of $0.
• On March 3, 2026, 121 shares were withheld by the Issuer to satisfy tax withholding obligations related to the vesting of restricted stock units, calculated at a closing price of $35.97.
• Following these transactions, Robb directly beneficially owns 79,503 shares of common stock.
• Robb also indirectly beneficially owns 11,571 shares in a custodial account for a child under the Uniform Transfers to Minors Act.
• The direct beneficial ownership includes several tranches of unvested restricted stock awards granted on various dates in 2025, which will vest on their one-year anniversaries.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive due to the insider purchase of shares, which signals confidence, balanced by the routine nature of the other transactions.

Positives

• Chief Business Officer Gary Charles Robb purchased 499 shares of common stock at $35.97, indicating management's confidence in the company.
• Robb received 499 unvested restricted stock awards, aligning his interests with long-term shareholder value.

Negatives

• 121 shares were withheld for tax obligations, a routine event but represents a reduction in direct holdings.

Risks

• The vesting of restricted stock awards is contingent upon the Reporting Person satisfying certain requirements, including remaining the beneficial owner of Purchase Plan Shares through the one-year anniversary for some awards.

Future Outlook

The filing indicates future vesting events for restricted stock awards, with 100% of shares vesting on the one-year anniversary of their respective grant dates, provided certain requirements are met.

Management Comments

• The price for the purchased shares was established based on the closing price on the day of the purchase.
• Shares were withheld by the Issuer to satisfy tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that insider purchases, even of relatively small amounts, can be interpreted by the market as a signal of management's belief in the company's future prospects, especially in the biotechnology sector where future drug development and regulatory approvals are key drivers.

Comparison to Industry Standards

• StockSavvy.ai observes that executive compensation packages in the pharmaceutical and biotechnology industries frequently include significant equity components, such as restricted stock awards, to align executive incentives with long-term shareholder value.
• The vesting schedule of one-year anniversaries for these awards is a common practice, similar to those seen at companies like Pfizer or Amgen, aiming to retain key talent and incentivize performance over a sustained period.

Stakeholder Impact

• Shareholders: Provides transparency into insider trading activity, potentially signaling management's confidence.
• Employees: The grant of restricted stock awards is a form of compensation and retention for the Chief Business Officer.

Next Steps

• Vesting of 292 shares underlying restricted stock awards on March 3, 2026 (one-year anniversary of grant).
• Vesting of 997 shares underlying restricted stock awards on June 2, 2026 (one-year anniversary of grant).
• Vesting of 251 shares underlying restricted stock awards on September 2, 2026 (one-year anniversary of grant).
• Vesting of 224 shares underlying restricted stock awards on December 1, 2026 (one-year anniversary of grant).
• Vesting of 499 shares underlying restricted stock awards on March 2, 2027 (one-year anniversary of grant), contingent on remaining beneficial owner of Purchase Plan Shares.

Key Dates

Recommendation

A Form 4 filing primarily discloses insider transactions and does not provide sufficient comprehensive financial or strategic information to warrant a 'buy' or 'sell' recommendation. The insider purchase, while a positive signal, is relatively small in the context of the executive's overall holdings and the company's market capitalization. Therefore, a 'hold' recommendation is appropriate, pending further comprehensive analysis of the company's financial performance and strategic outlook.

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Purchase, Restricted Stock Awards, Executive Compensation, Gary Charles Robb, Chief Business Officer